On June 11, GSK rose 3.01% in pre-market trading, trading at $52.62/share, with trading volume of $838,800. The rebound follows the initial sell-off triggered by the company's announcement of its record $10.6 billion acquisition of oncology-focused Nuvalent.

GSK confirmed the all-cash deal at $124 per share, representing a 40% premium over Nuvalent's prior closing price. The acquisition brings two late-stage non-small cell lung cancer drugs targeting specific genetic mutations, with FDA decisions expected later this year. CEO Luke Miels stated the deal will drive revenue growth starting in 2027 and strengthen core operating profit during the 2028-2030 patent cliff period as key HIV drug dolutegravir faces expiration. GSK reaffirmed its full-year guidance of 7%-9% growth in core operating profit and core EPS.

Analysts note the deal reflects urgency to rebuild GSK's oncology pipeline after exiting the space in 2015. Industry observers highlight the scarcity of near-commercial-stage precision oncology assets as justification for the premium, though integration risks and potential goodwill impairment remain concerns if clinical data underperform expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)